HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrea Carfi Selected Research

2019-nCoV Vaccine mRNA-1273

2/2022Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice.
1/2022Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
1/2022Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
12/2021Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
10/2021Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection.
10/2021Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
10/2021mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.
10/2021COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.
8/2021Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates.
5/2021Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrea Carfi Research Topics

Disease

22Infections
03/2024 - 07/2005
16COVID-19
01/2023 - 06/2020
6Weight Loss (Weight Reduction)
10/2023 - 01/2021
6Inflammation (Inflammations)
01/2023 - 10/2020
4Breakthrough Infections
02/2022 - 08/2021
3Communicable Diseases (Infectious Diseases)
01/2023 - 01/2022
2Severe Acute Respiratory Syndrome
03/2024 - 10/2021
2Virus Diseases (Viral Diseases)
01/2023 - 01/2012
2Pneumonia (Pneumonitis)
02/2022 - 08/2021
2Human Influenza (Influenza)
10/2015 - 01/2013
2Paramyxoviridae Infections (Parainfluenza)
10/2014 - 06/2011
1Smallpox (Variola)
10/2023
1Zika Virus Infection
04/2023
1Autoimmune Diseases (Autoimmune Disease)
01/2023
1Acquired Immunodeficiency Syndrome (AIDS)
12/2021
1Acute Lung Injury
10/2021
1Persistent Infection
01/2021
1Respiratory Tract Diseases (Respiratory Tract Disease)
10/2017
1Respiratory Syncytial Virus Infections
10/2014
1Bronchiolitis
06/2011
1Hypercholesterolemia
07/2007

Drug/Important Bio-Agent (IBA)

28VaccinesIBA
03/2024 - 06/2011
142019-nCoV Vaccine mRNA-1273IBA
02/2022 - 06/2020
12Neutralizing AntibodiesIBA
03/2024 - 06/2011
11mRNA VaccinesIBA
03/2024 - 08/2021
9Messenger RNA (mRNA)IBA
03/2024 - 01/2021
6Proteins (Proteins, Gene)FDA Link
02/2022 - 10/2014
5AntigensIBA
10/2023 - 06/2011
4AntibodiesIBA
01/2023 - 09/2015
4COVID-19 VaccinesIBA
12/2021 - 06/2020
3Glycoproteins (Glycoprotein)IBA
01/2018 - 06/2011
2Combined VaccinesIBA
10/2023 - 09/2022
2Viral AntigensIBA
05/2021 - 01/2021
2EpitopesIBA
01/2018 - 01/2012
1mRNA-1647 cytomegalovirus vaccineIBA
03/2024
1N-(2-cyanoethylene)urea (BA 1)IBA
01/2022
1N-methyl-valyl-amiclenomycin (BA 2)IBA
01/2022
1CytokinesIBA
01/2022
1RNA (Ribonucleic Acid)IBA
01/2022
1Protein Subunit VaccinesIBA
10/2021
1aluminum sulfate (alum)IBA
10/2021
1MF59 oil emulsionIBA
01/2018
1Immunoglobulins (Immunoglobulin)IBA
01/2016
1Influenza Vaccines (Influenza Vaccine)FDA Link
10/2015
1DisulfidesIBA
10/2014
1Respiratory Syncytial Virus VaccinesIBA
10/2014
1FurinIBA
10/2014
1Formaldehyde (Formol)FDA Link
10/2014
1Complementarity Determining Regions (Complementarity Determining Region)IBA
01/2013
1CD4 Antigens (CD4 Antigen)IBA
01/2012
1LDL CholesterolIBA
07/2007

Therapy/Procedure

1Therapeutics
07/2005